Congenital Athymia Patient Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-25

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.

Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tissue Repository for Studies of Myasthenia Gravis

NCT02902536

Myasthenia Gravis

COMPLETED

The Role of the Thymus in Myasthenia Gravis

NCT01102192

Myasthenia Gravis Thymoma

COMPLETED

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis

NCT05332587

Refractory Myasthenia Gravis Rituximab

UNKNOWN PHASE3

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

NCT06723548

Myasthenia Gravis Autoimmune Diseases

NOT_YET_RECRUITING PHASE4

Study of Telitacicept in Generalized Myasthenia Gravis

NCT05737160

Myasthenia Gravis, Generalized

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.

Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).

Currently, there is a single site where patients are being treated with RETHYMIC. The Investigator will be responsible for recruiting patients who have recently had (i.e., within the past 60 days) or are scheduled to have this treatment within 30 days and obtaining signed informed consent (and assent as applicable). The Investigator will collect baseline medical history and clinical data information for each enrolled subject. The start of follow-up (day 1) begins on the day following treatment surgery. Clinical data and flow cytometry test results (when conducted) will be abstracted from the medical records by Clinical Staff at baseline and during follow-up at predefined intervals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complete DiGeorge Anomaly Complete DiGeorge Syndrome Congenital Athymia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Main cohort

All eligible patients

Cultured Thymus Tissue

Intervention Type BIOLOGICAL

Product will be surgically administered into the quadriceps

Secondary cohort

All eligible patients who survived 1 year post treatment

Cultured Thymus Tissue

Intervention Type BIOLOGICAL

Product will be surgically administered into the quadriceps

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cultured Thymus Tissue

Product will be surgically administered into the quadriceps

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RETHYMIC allogeneic cultured thymus tissue-agdc

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric patients diagnosed with Congenital Athymia:

* Who are scheduled for implantation with RETHYMIC within the next 30 days, or who were treated with RETHYMIC within the previous 60 days.
* Who have provided written informed consent directly, or written informed consent has been provided by the patient, the parent, or legal guardian.